Treatment of Androgenetic Alopecia in Males
- Conditions
- Androgenetic AlopeciaHair LossMale Pattern Baldness
- Interventions
- Device: HairMax LaserComb 2009, 7 BeamDevice: HairMax LaserComb
- Registration Number
- NCT00947505
- Lead Sponsor
- Lexington International, LLC
- Brief Summary
The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 7 Beam model in promoting hair growth in males diagnosed with androgenetic alopecia when treatment is applied as directed.
- Detailed Description
This is randomized, double-blind, control device clinical study across 2 sites, evaluating changes in terminal hair-count in the evaluation zone having evidence of androgenetic alopecia (miniaturized hair).
The trial will involve 45 male subjects who have been diagnosed with androgenetic alopecia, who are between 25 and 60 years of age, have Fitzpatrick Skin Types I-IV, with classifications of Norwood-Hamilton IIa to V, have active hair loss within the last 12 months.
Subjects will use the device on three nonconcurring days a week as directed per device for 26 weeks treatment duration.
Initial efficacy endpoint for each subject will be assessed at visit 4 (week 16).
Safety analysis will be assessed based on the reports of adverse events during study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 49
- Diagnosis of androgenetic alopecia
- Fitzpatrick Skin Types I-IV
- Norwood-Hamilton IIa to V
- Active hair loss within last 12 months
- Photosensitivity to laser light
- Malignancy in the target area
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description HairMax LaserComb 2009, 7 Beam HairMax LaserComb 2009, 7 Beam Lower level laser phototherapy medical device with 7 laser beams Control Device HairMax LaserComb Identical to the Active device, but with 7 LED's instead of lasers
- Primary Outcome Measures
Name Time Method Changes in Terminal Hair Count at 16 and 26 Weeks Over Baseline 16 and 26 weeks Results of terminal hair count will be compared to baseline for each user between active and control devicea at 26 weeks with an interim evaluation at week 16. Terminal hair count, which is non-vellus/non-miniaturized hair counts, will be assessed in the target region
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Abe Marcadis, M.D.
🇺🇸Palm Beach, Florida, United States
Michael Jarratt, MD
🇺🇸Austin, Texas, United States